Granulomatosis with Polyangiitis Clinical Trials

Find Granulomatosis with Polyangiitis Clinical Trials Near You

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

Status: Recruiting
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 17
Healthy Volunteers: f
View:

⁃ All Cohorts:

• Male or female participants must be aged 6 to \< 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.

• Body weight greater than (\>=) 15 kilograms (kg).

⁃ EGPA Cohort:

• Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than \[\>\] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).

• Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

⁃ HES Cohort:

• Documented HES diagnosis, defined as history of persistent eosinophilia \>1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.

• Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.

• AEC ≥1000 cells/µL at screening (Visit 1).

• Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Locations
United States
Colorado
Research Site
RECRUITING
Aurora
Ohio
Research Site
RECRUITING
Cincinnati
Research Site
RECRUITING
Highland Hills
Other Locations
Brazil
Research Site
RECRUITING
São Paulo
Canada
Research Site
RECRUITING
Toronto
France
Research Site
RECRUITING
Lille
Research Site
SUSPENDED
Montpellier
India
Research Site
RECRUITING
Ahmedabad
Israel
Research Site
RECRUITING
Petah Tikva
Mexico
Research Site
RECRUITING
Guadalajara
Netherlands
Research Site
RECRUITING
Rotterdam
Poland
Research Site
RECRUITING
Kielce
Research Site
NOT_YET_RECRUITING
Warsaw
Turkey
Research Site
RECRUITING
Altındağ
Research Site
RECRUITING
Istanbul
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-04-17
Estimated Completion Date: 2029-05-14
Participants
Target number of participants: 14
Treatments
Experimental: EGPA/HES Cohort: Benralizumab
Participants with greater than or equal to (\>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (\<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov